AES 2017: Uniting the global epilepsy community and striving toward a world without epilepsy

• 

  Posted by
  Mike Davis, UCB U.S. Neurology Patient Value Unit
  01-Dec-2017

  As UCB prepares for the 2017 American Epilepsy Society (AES) annual meeting in Washington D.C. this week, it gives us time to reflect on the Society’s overall goal of working toward a world without epilepsy - a goal which is no doubt shared by everyone in the global epilepsy community.
  
  It certainly resonates with everyone involved with epilepsy at UCB: supporting patients in their journey towards seizure freedom underpins everything we do.
  
  At the AES meeting, as part of our commitment to helping make this goal a reality, UCB will be sharing 25 scientific posters – a great illustration of the extent to which, as a company, we’re inspired by patients and driven by science. The posters include new research and data about some of our current epilepsy medicines as well as exciting new information about prospective pipeline candidate medicines. In the future, these new solutions could provide new treatment options for patients with drug-resistant epilepsy or pediatric epileptic encephalopathies such as infantile spasms.
  
  We’ll also be presenting a wide range of data including results from a social media survey to access perceptions of patient information leaflets and pre-clinical data identifying a potential target receptor for epilepsy therapy.
  
  Alongside our scientific data, we look forward to further demonstrating and reinforcing our overarching passion for neurology and our commitment to addressing and improving the lives of people living with epilepsy.
  
  Throughout AES 2017, at our Outcomes Accelerator and Catalyst Café, UCB colleagues will be facilitating interactive conversations with delegates and focusing on how, together, we can ‘’#RiseAbove’ expectations of care for people with epilepsy. Harnessing innovative technologies, such as a virtual reality seizure simulation, we hope to demonstrate some of the realities faced by people with epilepsy and to support the global epilepsy community in addressing some of these challenges.
  
  We’ll also showcase collaborations which are already making a difference and sharing real-world examples of positive interventions such as the UCB Scholars Program and Canine Assistants partnership which deliver significant value to people with epilepsy.
  
  Our global epilepsy commitment, along with more than 20 years of  research, development and marketing of medicines for epilepsy, requires agility, interaction, and collaboration with leading experts and patient organizations across the world. We continue to work to address the significant unmet needs that still exist to support people in managing their epilepsy.
  
  Providing additional value to patients, and striving to ensure that all our stakeholders – be they customers, doctors, healthcare providers – are able to benefit from our epilepsy knowledge, passion, and experience is central to everything we do at UCB.
  
  Together with the AES, and the global epilepsy community, we are committed to improving the care and treatment of people with epilepsy, and to supporting them on their journey towards seizure freedom – helping them to live their lives at their ideal.
  
  In these endeavors, we are proud to stand alongside the AES and the wider epilepsy community in working toward a world without epilepsy.
  
  
  Tags:
  • AES
  • epilepsy
  
  Categories:
  • Our company
  
  Share: